Study objective: Although several trials have been published evaluating intravenous magnesium sulfate as treatment for acute bronchospasm, its effectiveness for this indication remains unclear, prompting this meta-analysis.
As both the incidence and mortality of asthma increase, so does interest in new effective treatments. As maintenance therapy for chronic bronchospasm, the introduction of frequent inhaled β 2 -agonists and anticholinergics, leukotriene inhibitors, inhaled steroids, and inhaled cromolyn sodium have improved the outpatient regimen, supplanting aminophylline therapy. For acute exacerbations, intravenous and oral steroids, continuous nebulized β 2 -agonists, and nebulized anticholinergics are the mainstays of treatment, as epinephrine use wanes. Still, acute decline into status asthmaticus remains a tenacious problem. For this reason, several alternative treatments, such as intravenous magnesium, are in growing use. Interest in the bronchodilating effects of magnesium dates back half a century to the reports of Rosello and Haury. 1 More recently, researchers attempting to elucidate magnesium's mechanism have focused primarily on its calcium antagonist properties, which inhibit calciummediated smooth muscle contraction. 2 Other proposed mechanisms include interference with parasympathetic stimulation 2 and potentiation of β 2-agonist effects. 1 In 1989, Skobeloff et al 3 published the first double-blind, placebo-controlled, randomized clinical trial, suggesting the beneficial effect of intravenous magnesium in the setting of an acute asthma exacerbation. Since that study, several other authors have attempted to replicate this finding, with variable results. Recently, meta-analysts affiliated with the Cochrane Group published a systematic review on the subject, concluding in a stratified analysis of 7 trials that intravenous magnesium sulfate therapy was beneficial in severe asthma. 4 Because the treating physician often cannot differentiate bronchospasm related to asthma from that caused by chronic obstructive pulmonary disease (COPD), both are included here. The purpose of this meta-analysis was to determine whether the addition of intravenous magnesium to standard therapy improves acute bronchospasm.
M A T E R I A L S A N D M E T H O D S
One author (HJA) identified the trials using 2 search algorithms on MEDLINE covering 1966 to 1998, with no language restriction: (1) [asthma OR whee*] AND magnesium; and (2) [asthma OR COPD OR "chronic obstructive pulmonary disease"] AND magnesium. The search author then replicated the algorithms on the Drugs & Pharmacology EMBASE database covering 1990 to 1998, its dates of electronic access. We then reviewed the bibliographies and attempted to query authors of relevant clinical research and review articles. To capture recent unpublished trials, we reviewed abstracts from 5 years of scientific meetings of 4 specialty societies: the Society for Academic Emergency Medicine, the American Thoracic Society, the American College of Chest Physicians, and the European Respiratory Society. The search author reviewed all abstracts for eligibility.
We determined a priori that trials meeting the following criteria would be eligible for inclusion: ED or equivalent setting with acutely ill patients; acutely bronchospastic trial subjects; and random assignment of patients to receive bolus dosing of either intravenous magnesium sulfate or placebo. We did not specify a priori a dose of magnesium, because of a paucity of evidence on doseresponse mechanics, or a method of blinding, or a specific spirometric outcome.
Studies specifically excluded from the review included case reports and case series, studies not specifying the clinical condition (ie, acute versus stable asthma), and those in which magnesium was not delivered intravenously.
The following data were abstracted in an unblinded fashion from each included study: author, country, year and source of publication, number of treatment arms, number of subjects in each arm, their inclusion criteria, whether all were accounted for, method of blinding, number and dosage of all medications used, outcome measures and approach to assessing them, means and SDs of the baseline and outcome data for each arm, time of posttreatment measurement, and incidence of complications.
We chose as the main outcome of interest peak expiratory flow rate (PEFR) where available, because this is a spirometric result easily available to emergency clinicians, and widely used and understood.
All but 3 studies used PEFR as a clinical outcome. Several studies also used FEV 1 , and 2 trials used only this measure. Our analysis used PEFR when available to promote comparability. All but 3 studies also reported hospitalization rates as an outcome measure.
Several studies reported their results in graphical form only, without corresponding numerical values. To determine estimates of these effects, graphs were photostatically enlarged, and the height of the data point and length of the error bars were measured in millimeters from the datum. This distance was converted to outcome units by which symmetry about the line of no effect suggests little influence of publication bias. 11 We also used a linear regression model proposed by Egger et al 12 for quantifying funnel plot asymmetry, which regresses the effect size divided by its standard error against the inverse of the standard error, a measure of precision. This test uses a value of P less than .1 to judge the significance of the intercept's dispersion from the origin as a means of judging asymmetry of the funnel plot. To further assess the potential for publication bias, correlation between effect size and the number of subjects in each study was explored using Spearman rank correlation. Following the precedent of Oler et al, 13 this analysis assumes that since "small studies with negative results were less likely to be published, then the correlation…would be high" in the setting of frank bias.
A sensitivity analysis examined the effects of calculating the summary result when certain studies were excluded. For example, this approach tests the effect on the summary result of excluding pediatric studies. We used this method also to explore the influence of study quality on the overall effect. For the purposes of the sensitivity analyses, we used the more conservative random-effects model.
R E S U L T S
The MEDLINE search and review of reference lists yielded 208 articles. Of these, 103 were unrelated to the specific measuring the units on the y axes, using a method previously published in the asthma literature. 5 In cases in which the graph or tables depicted SE, these were converted to SD by multiplying the reported value by the square root of the number of patients in that study.
Study quality was judged on a 5-point scale modified from Jadad et al. 6 This method assigns 1 point for each ordered criterion: randomization; blinding; descriptions of procedures for withdrawals and dropouts; descriptions of procedures for appropriate randomization and finally, 5 points total if all prior criteria are met and there is a description of an appropriate blinding procedure.
Because of the absence of a common outcome, a unitless summary effect size was estimated for each study, according to the technique known as Hedges' g, 7 and later explicated by Pettiti 8 (Appendix). This analysis yielded an estimate of the summary effect size and its 95% confidence limits (CIs), using modifications of both the fixedeffects method and of the random-effects method described by DerSimonian and Laird, 9 as appropriate (Appendix). The sample size was the absolute number of studies for each calculation. Combinability was explored with the Q statistic for heterogeneity, as described by Fleiss. 10 Studies were deemed to be not comparable under a fixedeffects model if Q was significant at values of P less than .05 (Appendix).
We explored publication bias using a funnel plot, in which study results are arrayed by sample size, and in the contributions of each trial to the calculation of the summary statistic. The effect size signifies the degree to which outcomes may vary relative to their SDs. In this analysis, the summary effect size of 0.162 suggests that the intervention improved the outcome of interest by 16% of its SD in a population. In this setting, for example, the pooled SD of the 6 adult studies reporting peak flow was ±101 L/min. The more conservative random-effects summary result of these 6 trials was 0.127 (95% CI -0.016, 0.265; P=.08). Thus, we can estimate that the addition of intravenous magnesium sulfate to standard therapy will, on average, improve peak flow by approximately 0.127×101=12.8 L/min compared with placebo.
The Q statistic, which denotes the degree of heterogeneity among the study populations, was 13.9 (P=.084). The fixed-effects model, which may be used when betweenstudies variation is not significant, assumes that each study represents an estimate of a true effect that is common to all studies. The random-effects model, which assumes that the trials represent a random sample of a universe of trials exploring a given effect, allows for random variability both within and between studies, and generally yields more conservative results. Using the random-effects model, our summary effect was slightly larger, 0.181 (95% CI -0.010, topic of interest, or were related only to properties of endogenous magnesium. Fifty-one articles were general reviews, either of asthma management or uses of magnesium, or letters containing no new trial data. Nineteen articles dealt with the pharmacology of administered magnesium, such as trials of intravenous magnesium sulfate therapy in induced conditions, [14] [15] [16] or effects or intravenous magnesium sulfate on cell biology. Eight articles were excluded because of nonacute or inpatient settings, [17] [18] [19] [20] [21] [22] [23] [24] and 9 because they examined the effect of inhaled magnesium. [25] [26] [27] [28] [29] [30] [31] [32] [33] Eleven articles described uncontrolled case series or case reports of intravenous magnesium therapy in acute bronchospasm.
1,16,34-42 The remaining 7 articles described randomized ED-based trials eligible for inclusion. 3, [43] [44] [45] [46] [47] [48] The EMBASE search yielded no further articles, but the abstract review and author consultation procedures resulted in the identification of 2 published abstracts containing trial data. 49, 50 The 9 final studies are depicted in the Table. All 9 were placebo-controlled studies and all but 1 were doubleblind 47 ; in this study, only the patients were blinded. All trials randomly allocated subjects to receive placebo or intravenous magnesium sulfate therapy, except for one, which instituted experimental and control treatments on alternate days. 47 The total number of studied patients was 859.
In 4 studies, 43, 45, 47, 49 the dose of magnesium was 2.0 g; in 1 study, an analogous dose of 25 mg/kg was used. 44 In 3 studies, a smaller 1.2-g dose was used 3,46,50 ; in 1 trial, a similarly smaller weight-based dose of 10 mg/kg was administered. 48 In studies using both a continuous infusion arm and a bolus arm, only the bolus arm was examined. All published protocols specified a 20-minute infusion period, and defined measurement times from the initiation of the bolus.
Each of the trials attempted to exclude mild exacerbations, either with a fixed maximum threshold for baseline PEFR or FEV 1 , 3,45,46,50 a maximum threshold for baseline against predicted performance, 43,44,48-50 or with a determination by the treating physician (before randomization) that a patient required intravenous steroid treatment. 47 The threshold severity of illness varied among the trials, from FEV 1 of less than 75% of the predicted value, 43 to a PEFR of less than 30% of predicted. Two studies focused exclusively on children, 44, 48 and 1 attempted to include only patients with an exacerbation of COPD. There were no reports of major adverse events requiring treatment.
The summary effect size using the fixed-effects model was 0.162 (95% CI 0.028, 0.297; P=.02). Figure 1 shows 
Individual and summary effect sizes for 9 trials. The trials are arrayed by sample size with the smallest at the top. Black boxes represent point estimates whose area is proportionate to sample size; bars represent 95% CI. Open diamond represents summary estimate of effect size and its 95% CI using a fixed-effects model. The vertical line at an effect size=0 is the line of no effect. The effect size is calculated by the method described by Rosenthal 7 in Cooper and Hedges (see Appendix).
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D I S C U S S I O N
The 9 trials constituting this meta-analysis, taken individually, present a paradoxical picture, with 4 authors reporting no statistically significant benefit to intravenous magnesium, 43, 45, 47, 50 and 5 reporting a statistically significant improvement in outcome among patients given this drug. 3, 44, 46, 48, 49 The finding of the meta-analysis of 9 trials involving 859 patients, with a statistically significant positive point estimate and no major adverse events, provides statistical support to those seeking to optimize patient outcomes in acute bronchospasm. This result is consistent, although not duplicative, of the findings of a recent related meta-analysis. Rowe et al 4 used the Cochrane analytic framework to examine the effect of intravenous magnesium sulfate on acute asthma. Their study excluded one trial included herein because it focuses on patients with COPD, 46 and another for reasons not made clear in the abstract, possibly because it fell outside of the search protocol. These authors also analyzed post hoc stratification by severity, thus concluding that the drug was useful only in severe exacerbations. As we sought to use data only from the trials as designed, we did not perform such a selective analysis. 0.327; P=.06), but barely crossed the line of no effect. Heterogeneity was decreased substantially by the exclusion of the positive and negative outlier studies 44, 45 ; in this analysis, the Q is 7.5 (P=.28), without substantial effect on the summary result, now 0.155 (95% CI 0.015, 0.295; P=.03) in a fixed-effects model. Figure 2 illustrates one attempt to address the question of publication bias. The studies are arrayed by sample size in a "funnel plot," with the largest at the top. Relative symmetry and clustering around the line of no effect suggests that publication bias plays little role in the result. A regression model relating the standard normal deviate to study precision yielded an intercept of 1.4 (P=.32), suggesting statistically insignificant asymmetry. Another means of exploring this question, correlating sample size with effect size, yielded a Spearman' s ρ of -0.20, suggesting a small but not statistically significant inverse relation. This result supports the finding in the funnel plot.
To test the sensitivity of the summary result to study quality and other idiosyncrasies among specific trials, we recalculated summary effect sizes excluding one study per iteration. In Figure 3 , the recalculated effects are arrayed in descending order of the Jadad score of the excluded trial. The observed pattern suggests that the exclusion of no single study, for quality or other reason, importantly alters the main finding. We also explored Our effect size, roughly 0.16, parallels the result of a recent meta-analysis of another adjuvant, inhaled ipratropium bromide, in acute asthma. 51 Rodrigo et al 51 summarized 10 trials studying 1,483 adults; their summary effect size was 0.14 (95% CI 0.04, 0.24).
S E P T E M B E R
The basic science behind the bronchodilatory effect of magnesium provides substantial biologic plausibility for our finding, and has been well studied both in vitro and in vivo. Its smooth muscle-relaxing effects operate independently of the β 2 -receptor, which suggests an adjunctive role, 25 and its parenteral administration allows magnesium to be delivered without interfering with inhaled therapy.
This study has several limitations. Results from our use of data gleaned from graphs may have led to some loss of precision. This shortcoming was unlikely to introduce a systematic bias, as both placebo and magnesium recipients were measured by the same technique. Also, we included data from both pediatric and adult populations, which may respond differently to medications. Our sensitivity analysis suggests that the adult finding is robust to the exclusion of the 2 small pediatric studies.
Finally, the summary estimate is only as good as the data contributing to its formulation. However, these are the same data that comprise the literature. We elected not to use hospital admission, which some may consider a more meaningful endpoint, as the outcome of analysis because of several sources of potential bias. For example, in at least 2 studies, consideration for admission appeared to be related to an inclusion criterion. 44, 48 In another study, the clinicians were not blinded to treatment assignment, 47 which may have influenced the admission decision. We also believed that, although regional variation in admission practices might not result in bias within a study, it would introduce substantial heterogeneity between the studies.
Two other sources of heterogeneity may influence our result in ways that are difficult to assess. The Table shows the varying degrees of severity among enrolled patients, as well as the fact that steroid use, and the dose administered, also varied widely. However, our summary result demonstrates nonsignificant between-study heterogeneity, suggesting that such effects may be unrelated to the true effect of intravenous magnesium sulfate therapy.
Our clinical example, using the pooled SD of adult trials reporting PEFR, is one way of assessing the small clinical benefit of intravenous magnesium sulfate therapy. Cohen 52 has proposed another, an operational convention for the significance of effect sizes, in which those less than 0.2 are by definition considered "small," those in the range of 0.5 are defined as "medium," and effect sizes around a value of 0.8 are known as "large." Given the known safety of the drug and its relatively low cost, the addition of intravenous magnesium sulfate therapy should be considered, absent contraindications, in patients with moderate to severe bronchospasm. This recommendation should be refined in the future by an analysis of the cost-effectiveness of such an approach. 
A P P E N D I X

Formulas used to derive results
According to the technique known as Hedges' g, 7 and later explicated by Pettiti, 8 effect size can be quantified as a quotient expressed as:
where d I measures effect size in the ith study, mean e is the mean in the experimental group, mean c is the mean in the control group, and SD pi is the pooled estimate of the SD of the effect measure for each study, or of the control group. The effect size thus relates mean differences between treatment groups to the SD. The sampling variance of d I was then estimated by the equation: The standard error was taken as the square root of the variance. The "meta" procedure in the Stata statistical package 53 was used to obtain a weighted average of the d I across studies, weighting each d I by the inverse of its estimated sampling variance, using the following computational methods.
The fixed-effects model is calculated assuming a true treatment effect across studies: The test for comparability, or heterogeneity across studies, is:
Q has a χ 2 k-1 distribution.
The random-effects model uses an estimator of between-studies variation, τ 2 :
The studies are combined in a fashion similar to the fixed-effects model, only in this case w i = 1/(v i + τ 2 ) for both θ R and the variance of θ R . For this reason, w i is sometimes denoted w* i .
